78. Hypopituitarism Clinical trials / Disease details


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04897802
(ClinicalTrials.gov)
September 13, 202117/5/2021Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin DeficiencyDrug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administrationFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauInstituto de Salud Carlos IIIRecruiting18 Years65 YearsAll52Phase 4Spain
2EUCTR2020-004115-27-ES
(EUCTR)
10/05/202101/09/2021Identification and clinical relevance of oxytocin deficient status: GLP1 studyIdentification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-controlled pathophysiological pilot study: GLP1 study Hypopituitarism;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Byetta
INN or Proposed INN: EXENATIDE
Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant PauNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
52Phase 2Spain